Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9843582 | 0.88 | OPRM1 (0.60) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Racemoramide SCHEMBL25463 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Racemoramide SCHEMBL548434 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Levomoramide SCHEMBL907811 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL22313008 | 0.85 | LMNA (0.49) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL11141154 | 0.84 | LMNA (0.49) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Racemoramide SCHEMBL7474188 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Racemoramide SCHEMBL548433 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL9917087 | 0.80 | SMN1; SMN2 (0.47) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL22313198 | 0.79 | KDM4E (0.51) | ALDH1A1LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536138-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024261775-A1 | A DRUG-ANTAGONIST COMBINATION DOSAGE FORM | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024211329-A2 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4373484-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-3054934-B1 | METHODS AND COMPOSITIONS FOR TREATING WITHDRAWAL SYNDROMES USING NON-SEDATIVE DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA INC (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024044315-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023244797-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244821-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023003810-A1 | COMPOSITIONS AND METHODS FOR TREATING OPIOID DEPENDENCE AND WITHDRAWAL | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| EP-3107546-A2 | THERAPEUTIC METHODS EMPLOYING NORIBOGAINE AND RELATED COMPOUNDS | DemeRx, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-3107545-A1 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF DRUG ADDICTION | DemeRx, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015126836-A2 | THERAPEUTIC METHODS EMPLOYING NORIBOGAINE AND RELATED COMPOUNDS | DEMERX, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015126434-A1 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF DRUG ADDICTION | DEMERX, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | ALDH1A1 1246/4885LMNA 156/4885MEN1 4716/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | ALDH1A1 1956/4885LMNA 619/4885MEN1 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.